Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2017, the company has rapidly established itself as a leader in developing innovative therapies for ocular diseases, particularly focusing on unmet medical needs in the eye care sector. Tarsus is renowned for its flagship product, TP-03, a groundbreaking treatment for Demodex blepharitis, which sets itself apart through its targeted mechanism of action and potential to transform patient care. With a commitment to advancing ocular health, Tarsus has achieved significant milestones, including successful clinical trials and strategic partnerships that bolster its market position. As it continues to expand its operational reach, Tarsus Pharmaceuticals remains dedicated to delivering unique solutions that enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Tarsus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tarsus Pharmaceuticals, Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tarsus Pharmaceuticals, Inc.'s reported carbon emissions
In 2021, Tarsus Pharmaceuticals, Inc. reported total carbon emissions of approximately 108,374,000 kg CO2e from Scope 1, 57,416,000 kg CO2e from Scope 2, and 24,048,000 kg CO2e from Scope 3 emissions. This indicates a significant increase in emissions compared to 2020, where the company recorded approximately 73,254,000 kg CO2e in Scope 1, 59,371,000 kg CO2e in Scope 2, and 1,670,000 kg CO2e in Scope 3. Despite the increase in emissions, Tarsus Pharmaceuticals has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments or reduction strategies suggests that the company may still be in the early stages of developing a comprehensive sustainability plan. As a pharmaceutical company headquartered in the US, Tarsus Pharmaceuticals operates within an industry increasingly focused on climate action and sustainability. The lack of specific targets highlights an opportunity for the company to enhance its climate commitments and align with industry standards for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 73,254,000 | 000,000,000 |
| Scope 2 | 59,371,000 | 00,000,000 |
| Scope 3 | 1,670,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tarsus Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
